780 related articles for article (PubMed ID: 7986116)
21. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).
Lehmann J; Retz M; Wiemers C; Beck J; Thüroff J; Weining C; Albers P; Frohneberg D; Becker T; Funke PJ; Walz P; Langbein S; Reiher F; Schiller M; Miller K; Roth S; Kälble T; Sternberg D; Wellek S; Stöckle M;
J Clin Oncol; 2005 Aug; 23(22):4963-74. PubMed ID: 15939920
[TBL] [Abstract][Full Text] [Related]
22. [Neoadjuvant chemotherapy (M-VAC) in invasive cancer of the bladder. Our experience].
González Enguita C; Caro Cebrián C; Roncalés Badal A; Gil Sanz MJ; Martínez Bengoechea J; Rioja Sanz LA
Arch Esp Urol; 1990; 43 Suppl 2():197-204. PubMed ID: 2096779
[TBL] [Abstract][Full Text] [Related]
23. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan.
Matsui Y; Nishiyama H; Watanabe J; Teramukai S; Ono Y; Ohshima S; Fujimoto K; Hirao Y; Fukushima M; Ogawa O
Int J Clin Oncol; 2005 Apr; 10(2):133-8. PubMed ID: 15864700
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
Muramaki M; Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818
[TBL] [Abstract][Full Text] [Related]
25. [Polychemotherapy using the M-VEC protocol (methotrexate, vinblastine, epirubicin, cisplatin) in advanced urinary bladder cancer--effectiveness and toxicity].
Rassweiler J; Rüther U; Bäuerle K; Bub P; Jipp P; Eisenberger F
Urologe A; 1989 Jan; 28(1):25-30. PubMed ID: 2922897
[TBL] [Abstract][Full Text] [Related]
26. Study of the prediction system for clinical response to M-VAC neoadjuvant chemotherapy for bladder cancer.
Takata R; Obara W; Fujioka T
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S41-5. PubMed ID: 20094952
[TBL] [Abstract][Full Text] [Related]
27. [Neoadjuvant chemotherapy of locally advanced tumors of the bladder: preliminary experience].
Ruoppolo M; Bellorofonte C; Gritti A; Gozo M; Ferri PM; Tura M; Zaatar C; Tiraboschi B; Morosini D; Dell'Acqua S
Arch Ital Urol Nefrol Androl; 1990 Jun; 62(2):243-8. PubMed ID: 2142808
[TBL] [Abstract][Full Text] [Related]
28. Phase I-II pilot study on the efficacy and tolerability of neoadjuvant chemotherapy (Rescue M-VEC) and preoperative radiation therapy for infiltrating bladder cancer: results of an 18-month follow-up.
Voce S; Montanari F; Arnone S; Dal Pozzo C; Suprani G; Cerullo G; Fornarola V
Arch Esp Urol; 1992 Jun; 45(5):491-8. PubMed ID: 1510485
[TBL] [Abstract][Full Text] [Related]
29. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer.
Freiha F; Reese J; Torti FM
J Urol; 1996 Feb; 155(2):495-9; discussion 499-500. PubMed ID: 8558644
[TBL] [Abstract][Full Text] [Related]
30. [Preliminary results of a phase II randomized controlled trial comparing M-VAC and M-CAVI in patients with bladder cancer (T2-4 N0-1 M0)].
Bellmunt Molins J; Ribas A; Albanell J; Lorente Garín JA; de Torres Mateos JA; Morote Robles J; López Palacios MA; Banús Gassol JM; Casado Cobo S; Eres N; Solé Calvo LA
Arch Esp Urol; 1996 Jun; 49(5):465-72. PubMed ID: 8766083
[TBL] [Abstract][Full Text] [Related]
31. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
[TBL] [Abstract][Full Text] [Related]
32. [Prognosis in pT3b infiltrating tumors of the bladder treated by adjuvant chemotherapy].
Sahwi A; Robert M; Delbos O; Legouffe E; Guiter J; Navratil H
Prog Urol; 1998 Dec; 8(6):1007-11. PubMed ID: 9894259
[TBL] [Abstract][Full Text] [Related]
33. [Study of neoadjuvant chemotherapy for invasive bladder cancer with MEC (methotrexate, epirubicin, cisplatin) therapy].
Ohuchi H; Noguchi S; Takase K; Kawakami S; Ikeda I; Saito K; Yao M; Masuda M; Kubota Y; Hosaka M
Hinyokika Kiyo; 2001 Apr; 47(4):241-6. PubMed ID: 11411097
[TBL] [Abstract][Full Text] [Related]
34. [Neoadjuvant chemotherapy of infiltrating carcinoma of the bladder: our experience].
Graziotti P; Personeni A; Benzone S; Giannone C; Giardina G; Guizzetti C; Ranieri A; Romano C; Taino R; Lembo A
Arch Ital Urol Nefrol Androl; 1990 Jun; 62(2):223-9. PubMed ID: 2142805
[TBL] [Abstract][Full Text] [Related]
35. [Chemotherapy of invasive bladder cancer].
Kotake T
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2375-82. PubMed ID: 1952956
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin-based neoadjuvant chemotherapy for invasive bladder cancer.
Kadena H; Igawa M; Shigeta M; Nakamoto T; Usui T
Hiroshima J Med Sci; 1995 Dec; 44(4):129-32. PubMed ID: 8857236
[TBL] [Abstract][Full Text] [Related]
37. [MEP (methotrexate, etoposide and cisplatin) and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced uroepithelial cancer--a preliminary report of MEP as second line chemotherapy for recurrence after M-VAC].
Seguchi T; Nakano E; Miki T; Kondoh M; Nishimura K; Nakamura N; Okuyama A
Gan To Kagaku Ryoho; 1994 Jan; 21(1):59-65. PubMed ID: 8291917
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant treatment of cancer of the bladder with M-VAC/M-VEC, and bladder-sparing policy: preliminary report of a non-randomized study.
Galante E; Ferroni C; Bianchi S; Megale C; Molinaro S; Maymone S
J Exp Ther Oncol; 1996 Jul; 1(4):237-41. PubMed ID: 9414410
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of adjuvant chemotherapy in transitional cell carcinoma of the urinary bladder with lymph node involvement and/or lymphovascular invasion treated by radical cystectomy.
Park J; Park S; Song C; Doo C; Cho YM; Ahn H; Kim CS
Urology; 2007 Aug; 70(2):257-62. PubMed ID: 17826485
[TBL] [Abstract][Full Text] [Related]
40. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy.
Inoue K; Slaton JW; Karashima T; Yoshikawa C; Shuin T; Sweeney P; Millikan R; Dinney CP
Clin Cancer Res; 2000 Dec; 6(12):4866-73. PubMed ID: 11156246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]